PL EN


Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
1998 | 45 | 1 |

Tytuł artykułu

Actinomycin D specifically inhibits the interaction between transcription factor Sp1 and its binding site

Warianty tytułu

Języki publikacji

EN

Abstrakty

EN
The mode of action of many anticancer drugs involves DNA interactions. We here examine the ability of actinomycin D to alter the specific binding of transcription factors Sp1 and NFκB to their DNA sequences. Employing an electrophoretic mobility shift assay, it is shown that actinomycin D inhibits complex formation between nuclear proteins present in the extracts from stimulated human umbilical vein endothelial cells and the Sp1-binding site. Actinomycin D is also able to induce disruption of preformed DNA-protein complexes, pointing to the importance of an equilibrium of three components: actinomycin D, protein and DNA for drug action. The effect of actinomycin D is sequence-specific, since no inhibition is observed for interaction of nuclear proteins with the NFκB binding site. The results support the view that DNA-binding drugs displaying high sequence-selectivity can exhibit distinct effects on the interaction between DNA and different DNA-binding proteins.

Wydawca

-

Rocznik

Tom

45

Numer

1

Opis fizyczny

p.67-73,fig.

Twórcy

autor
  • Medical University of Lodz, W.Lindleya 6, 90-131 Lodz, Poland

Bibliografia

  • 1. Hurst, H.C. (1996) Transcription factors as drug targets in cancer. Eur. J. Cancer 32A, 1857-1863.
  • 2. Laughton, C.A., Jenkins, T.C., Fox, K.R. & Neidle, S. (1990) Interaction of berenil with the tyrT DNA sequence studied by footprints ing and molecular modelling. Implications for the design cf sequence-specific DNA recogni­tion agents. Nucleic Acids Res. 18,4479-4488.
  • 3. Churchill, M.E.A., Hayes, J J. & Tullius, T.D. (1990) Detection of drug binding to DNA by hydroxyl radical footprinting. Relationship of distamycin binding sites to DNA structure and positioned nucleosomes of 5S RNA genes of Xenopus. Biochemistry 29. 6043-6050.
  • 4. Van Dyke, W.W. & Dervan, P.B. (1983) Chromomycin, mithramycin and olivomycin binding sites on heterogenous DNA. Foot- printing with (methidium propyl-EDTA)iron (II). Biochemistry 22, 2373-2377.
  • 5. Stankus, A., Goodisman, J. & D^browiak, J.C. (1992) Quantitative footprinting analysis of the chromomycin A3-DNA interaction. Bio­chemistry 31, 9310-9318.
  • 6. Broggini, M. & D'lncalci, M. (1994) Modula­tion of transcription factor-DNA interac­tions by anticancer drugs. Anticancer Drug Design 9. 373-387.
  • 7. Bianchi, N., Passadore, M., Rutigliano, C., Feriotto, G., Mischiati, C. & Gambari, R. (1996) Targeting of the Spl binding sites of HIV-1 long terminal repeat with chromomy­cin — Disruption of nuclear factor-DNA complexes and inhibition of in vitro tran­scription. Biochem. Pharmacol. 52, 1489- 1498.
  • 8. Muller, J.M., Ziegler-Heitbrock, H.W.L. & Baeuerle, P.A. (1993) Nuclear factor kappa B, a mediator of lipopolysaccharide effects. Im- munobiology 187, 233-256.
  • 9. Donahue, J.P., Sugg,N. & Hawiger.J. (1994) The integrin av gene: Identification and characterization of the promoter region. Biochim. Biophys. Acta 1219, 228-232.
  • 10. Jaffe, E.A., Nachlman, R.L., Becker, C.G. & Minick, C.R. (1973) Culture of human endo­thelial cells derived from umbilical veins. J. Clin. Invest. 53, 2745-2756.
  • 11. Dignam, J.D., Lebovitz, R.M. & Roeder, R.G. (1983) Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res. 11, 1475-1489.
  • 12. Moll, T., Czyz, M., Holzmuller, H., Hofer- Warbinek, R., Wagner, E., Winkler, H.. Bach, F.H. & Hofer.E. (1995) Regulation of the tissue factor promoter in endothelial cells. J. Biol Chem. 270, 3849-3857.
  • 13. Sambrook, J., Fritsch, E.F. & Maniatis, T. (1989) in Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
  • 14. Mac Leod, M.C., Powell, K.L., Kuzmin, V.A., Kolbanovskiy, A. & Geacintov, N.E. (1996) In­terference of benzoialpyrene diol epoxide-deoxyguanosine adducts in a GC box with binding of the transcription factor Spl. MoL Carcinogenesis 16, 44-52.
  • 15. Gray, P.J. (1995) Sulphur mustards inhibit binding of transcription factor AP 2 in vitro. Nucleic Acids Res. 23, 4378-4382.
  • 16. Welch, J.J., Rauscher, F.J. Ill & Beerman.T.A. (1994) Targeting DNA-binding drugs to sequence-specific transcription factor-DNA complexes. J. Biol. Chem. 269,31051-31058.
  • 17. Gale, E.F., Cundliffe, E., Reynolds, P.E., Richmond, M.H. & Waring, M.J. (1981) In­hibitors of nucleic acid synthesis; in The Mo­lecular Basis of Antibiotic Action; pp. 258-401, J. Wiley, N.Y.
  • 18. Piestrzeniewicz, M.K., Wilmanska, D., Studz- ian, K., Szemraj,J., Czyz, M., Denny, W.A. & Gniazdowski, M. (1997) Inhibition of RNA synthesis in vitro by acridines— Relation between structure and activity. Z. Natur- forsch., in press.
  • 19. Kee, A.H., Maelandsme, G.M. & Kodstad, O. (1996) Regulation of matrix metallopro teinase-1 and tissue inhibitor of metallo- proteinase-1 in MCF-7 cells: Comparison with regulatory mechanisms of pS2 expression. Clin. Exp. Metastasis 14, 381-388.
  • 20. Jaros-Kamiń8ka, B., Małagocka, E., Ciesiel­ska, E. & Gniazdowski, M. (1981) Compari­son of inhibitory effect of various drugs on yeast and bacterial RNA polymerases. Studia Biophys. 86, 211-218.
  • 21. Atwell, G.J., Baguley, B.C., Wilmanska, D. & Denny, W.A. (1986) Potential antitumor agents. 45. Synthesis, DNA-binding interac­tion, and biological activity of triacridine derivatives.

Typ dokumentu

Bibliografia

Identyfikatory

Identyfikator YADDA

bwmeta1.element.agro-article-ac7f0503-22a0-4c44-9b2b-f6f6339a05bf
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.